Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep:61:101112.
doi: 10.1016/j.blre.2023.101112. Epub 2023 Jun 29.

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink

Affiliations
Review

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink

Tomás José González-López et al. Blood Rev. 2023 Sep.

Abstract

There are not many publications that provide a holistic view of the management of primary and secondary ITP as a whole, reflecting the similarities and differences between the two. Given the lack of major clinical trials, we believe that comprehensive reviews are much needed to guide the diagnosis and treatment of ITP today. Therefore, our review addresses the contemporary diagnosis and treatment of ITP in adult patients. With respect to primary ITP we especially focus on establishing the management of ITP based on the different and successive lines of treatment. Life-threatening situations, "bridge therapy" to surgery or invasive procedures and refractory ITP are also comprehensively reviewed here. Secondary ITP is studied according to its pathogenesis by establishing three major differential groups: Immune Thrombocytopenia due to Central Defects, Immune Thrombocytopenia due to Blocked Differentiation and Immune Thrombocytopenia due to Defective Peripheral Immune Response. Here we provide an up-to-date snapshot of the current diagnosis and treatment of ITP, including a special interest in addressing rare causes of this disease in our daily clinical practice. The target population of this review is adult patients only and the target audience is medical professionals.

Keywords: Diagnosis; Primary immune thrombocytopenia (ITP); Refractory ITP; Secondary immune thrombocytopenia; Thrombopoietin receptor agonists (TPO-RAs); Treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Tomás José González-López has received research grants from Amgen and Novartis and speaker honoraria from Amgen, Novartis, Sobi, Grifols and Argenx. Drew Provan has received research support and honoraria from Amgen and Novartis and has acted as a consultant for UCB, MedImmune, Ono and Takeda. Dr. Jarque-Ramos reports consulting honorarium from Amgen, Novartis and Shionogi. Rest of authors declare no competing financial interests.

MeSH terms

LinkOut - more resources